Clinical Trial Update: Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of CINRYZE for prevention of angioedema attacks in children 6-11 with hereditary angioedema; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Cinryze (C1 esterase inhibitor)

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: COMPLETED | Results posted: 2018-08-28